Julio Lamprea Montealegre, MD, PhD, MPH
Assistant Professor
Medicine
School of Medicine

Dr. Lamprea-Montealegre is a cardiologist who focuses on preventive cardiology. His clinical interests include preventive cardiology and cardiovascular risk assessment, cardiorenal syndrome, dyslipidemias , heart valve disease, and echocardiography. Dr. Lamprea-Montealegre's research focuses on the cardiovascular health consequences of chronic kidney disease. His current projects aim to prevent cardiovascular disease through the early detection and treatment of chronic kidney disease.

Education & Training

Show all (5) Hide

• Fellowship Cardiology University of Washington 06/2018
• Residency Internal Medicine University of Maryland 06/2015
• PhD Cardiovascular Epidemiology Johns Hopkins 06/2012
• MPH Epidemiology & Biostatistics Johns Hopkins 06/2009
• MD Universidad Javeriana 06/2006

Interests

Show all (6) Hide

• echocardiography
• dyslipidemia
• implementation science
• cardio-renal epidemiology
• preventive cardiology
• cardiovascular epidemiology

Websites

Show all (1) Hide

• @@jlampre on Twitter (twitter.com)

Grants and Projects

Show all (4) Hide

• Closing the Cardio-Renal Preventive Treatment Gap Among Patients with Type 2 Diabetes Mellitus and Chronic Kidney Disease: An Implementation Science Approach, NIH/NHLBI, 2022-2027
• Closing the Cardio-Renal Preventive Treatment Gap Among Patients with Type 2 Diabetes Mellitus and Chronic Kidney Disease: An Implementation Science Approach, NHLBI, 2024-2027
• Disparities in cardio-renal care provision among elderly patients of racial and ethnic minorities, UCSF CADC/NIA, 2021-2022
• The dyslipidemia of ESRD: role of triglyceride-rich lipoproteins and association with cardiovascular events, American Heart Association, 2018-2020

Publications (30)

Top publication keywords:
Renal Insufficiency, ChronicHeart Valve DiseasesCystatin CLipoproteinsAlbuminuriaPrescriptionsGlomerular Filtration RateGlucagon-Like Peptide-1 ReceptorTriglyceridesAtherosclerosisHealthy LifestyleApolipoprotein C-IIICardiovascular DiseasesCholesterol, VLDLDyslipidemias

• Challenges and Strategies in Implementing Novel Kidney Protective and Cardioprotective Therapies in Patients With Diabetes and Kidney Disease.
  Seminars in nephrology 2024 Limonte CP, Lamprea-Montealegre JA, Tuttle KR
• Assessing community-level impacts of and responses to stay at home orders: The King County COVID-19 community study.
  PloS one 2024 Moloney K, Lamprea Montealegre JA, Busch Isaksen TM, Kennedy M, Archer M, Contreras C, Iyaz D, Randazza J, Silva J, Errett NA
• Unlocking the potential: boosting SGLT2 inhibitor uptake to prevent the cardiorenal consequences of chronic kidney disease.
  The Lancet regional health. Western Pacific 2024 Lamprea-Montealegre JA
• Population-wide albuminuria screening: implications for CKD detection and management.
  Lancet (London, England) 2023 Lamprea-Montealegre JA, Estrella MM
• Estimated Prevalence and Testing for Albuminuria in US Adults at Risk for Chronic Kidney Disease.
  JAMA network open 2023 Chu CD, Xia F, Du Y, Singh R, Tuot DS, Lamprea-Montealegre JA, Gualtieri R, Liao N, Kong SX, Williamson T, Shlipak MG, Estrella MM

Show all (25 more) Hide

• Prescription Patterns of Cardiovascular- and Kidney-Protective Therapies Among Patients With Type 2 Diabetes and Chronic Kidney Disease.
  Diabetes care 2022 Lamprea-Montealegre JA, Madden E, Tummalapalli SL, Chu CD, Peralta CA, Du Y, Singh R, Kong SX, Tuot DS, Shlipak MG, Estrella MM
• Launching a career as a physician-scientist.
  Heart (British Cardiac Society) 2022 Lamprea-Montealegre JA, Natarajan P
• Improving chronic kidney disease detection and treatment in the United States: the chronic kidney disease cascade of care (C3) study protocol.
  BMC nephrology 2022 Lamprea-Montealegre JA, Joshi P, Shapiro AS, Madden E, Navarra K, Potok OA, Gregg LP, Podchiyska T, Robinson A, Goldstein MK, Peralta CA, Jassal SK, Navaneethan SD, Rifkin DE, Wang V, Shlipak MG, …
• Association of Race and Ethnicity With Prescription of SGLT2 Inhibitors and GLP1 Receptor Agonists Among Patients With Type 2 Diabetes in the Veterans Health Administration System.
  JAMA 2022 Lamprea-Montealegre JA, Madden E, Tummalapalli SL, Peralta C, Neilands TB, Garcia PK, Muiru A, Karliner L, Shlipak MG, Estrella MM
• Plasma Levels of Advanced Glycation Endproducts and Risk of Cardiovascular Events: Findings From 2 Prospective Cohorts.
  Journal of the American Heart Association 2022 Lamprea-Montealegre JA, Arnold AM, McCLelland RL, Mukamal KJ, Djousse L, Biggs ML, Siscovick DS, Tracy RP, Beisswenger PJ, Psaty BM, Ix JH, Kizer JR
• Improving cardiovascular health through healthy lifestyle behaviours: time to think beyond willpower.
  Heart (British Cardiac Society) 2022 Lamprea-Montealegre JA
• Too Many for Too Few: Finding Appropriate Nephrology Referrals for Patients With CKD That Optimize Outcomes.
  American journal of kidney diseases : the official journal of the National Kidney Foundation 2022 Chu CD, Lamprea-Montealegre JA, Estrella MM
• Valvular Heart Disease in Relation to Race and Ethnicity: JACC Focus Seminar 4/9.
  Journal of the American College of Cardiology 2021 Lamprea-Montealegre JA, Oyetunji S, Bagur R, Otto CM
• Coverage, Formulary Restrictions, and Affordability of Sodium-Glucose Cotransporter 2 Inhibitors by US Insurance Plan Types
  JAMA Health Forum 2021 Sri Lekha Tummalapalli; Julio Lamprea Montealegre; Neil Warnock; Michael Green; Said A. Ibrahim; Michelle M. Estrella
• Triglyceride-Rich Lipoproteins, Apolipoproteins, and Atherosclerotic Cardiovascular Events Among Patients with Diabetes Mellitus and End-Stage Renal Disease on Hemodialysis.
  The American journal of cardiology 2021 Lamprea-Montealegre JA, Katz R, Scharnagl H, Silbernagel G, März W, Drechsler C, Wanner C, de Boer IH
• Aortic and mitral valve calcification as markers of atherosclerotic cardiovascular disease risk.
  European heart journal. Cardiovascular Imaging 2021 Lamprea-Montealegre JA, Otto CM
• Chronic kidney disease detection, staging and treatment in cardiovascular disease prevention.
  Heart (British Cardiac Society) 2021 Lamprea-Montealegre JA, Shlipak MG, Estrella MM
• Apolipoprotein B, Triglyceride-Rich Lipoproteins, and Risk of Cardiovascular Events in Persons with CKD.
  Clinical journal of the American Society of Nephrology : CJASN 2019 Lamprea-Montealegre JA, Staplin N, Herrington WG, Haynes R, Emberson J, Baigent C, de Boer IH, SHARP Collaborative Group
• Association of High-Density Lipoprotein Particles and High-Density Lipoprotein Apolipoprotein C-III Content With Cardiovascular Disease Risk According to Kidney Function: The Multi-Ethnic Study of Atherosclerosis.
  Journal of the American Heart Association 2019 Lamprea-Montealegre JA, McClelland RL, Otvos JD, Mora S, Koch M, Jensen MK, de Boer IH
• Cardiac Biomarkers and Risk of Atrial Fibrillation in Chronic Kidney Disease: The CRIC Study.
  Journal of the American Heart Association 2019 Lamprea-Montealegre JA, Zelnick LR, Shlipak MG, Floyd JS, Anderson AH, He J, Christenson R, Seliger SL, Soliman EZ, Deo R, Ky B, Feldman HI, Kusek JW, deFilippi CR, Wolf MS, Shafi T, Go AS, Bansal N, …
• Prevalence of Hypertension and Cardiovascular Risk According to Blood Pressure Thresholds Used for Diagnosis.
  Hypertension (Dallas, Tex. : 1979) 2018 Lamprea-Montealegre JA, Zelnick LR, Hall YN, Bansal N, de Boer IH
• Reevaluating the Evidence for Blood Pressure Targets in Type 2 Diabetes.
  Diabetes care 2018 Lamprea-Montealegre JA, de Boer IH
• Effectiveness of informational decision aids and a live donor financial assistance program on pursuit of live kidney transplants in African American hemodialysis patients.
  BMC nephrology 2018 Boulware LE, Ephraim PL, Ameling J, Lewis-Boyer L, Rabb H, Greer RC, Crews DC, Jaar BG, Auguste P, Purnell TS, Lamprea-Monteleagre JA, Olufade T, Gimenez L, Cook C, Campbell T, Woodall A, Ramamurthi H…
• Coronary heart disease risk associated with the dyslipidaemia of chronic kidney disease.
  Heart (British Cardiac Society) 2018 Lamprea-Montealegre JA, McClelland RL, Grams M, Ouyang P, Szklo M, de Boer IH
• Health Behaviors and Calcific Aortic Valve Disease.
  Journal of the American Heart Association 2018 Lamprea-Montealegre JA, Otto CM
• Chronic kidney disease, lipids and apolipoproteins, and coronary heart disease: the ARIC study.
  Atherosclerosis 2014 Lamprea-Montealegre JA, Sharrett AR, Matsushita K, Selvin E, Szklo M, Astor BC
• Comparison of life participation activities among adults treated by hemodialysis, peritoneal dialysis, and kidney transplantation: a systematic review.
  American journal of kidney diseases : the official journal of the National Kidney Foundation 2013 Purnell TS, Auguste P, Crews DC, Lamprea-Montealegre J, Olufade T, Greer R, Ephraim P, Sheu J, Kostecki D, Powe NR, Rabb H, Jaar B, Boulware LE
• Chronic kidney disease, plasma lipoproteins, and coronary artery calcium incidence: the Multi-Ethnic Study of Atherosclerosis.
  Arteriosclerosis, thrombosis, and vascular biology 2013 Lamprea-Montealegre JA, McClelland RL, Astor BC, Matsushita K, Shlipak M, de Boer IH, Szklo M
• CKD, plasma lipids, and common carotid intima-media thickness: results from the multi-ethnic study of atherosclerosis.
  Clinical journal of the American Society of Nephrology : CJASN 2012 Lamprea-Montealegre JA, Astor BC, McClelland RL, de Boer IH, Burke GL, Sibley CT, O'Leary D, Sharrett AR, Szklo M
• Validity in scale-testing
  2007 Lamprea-Montealegre JA, Gomez-Restrepo C.